Wynik wyszukiwania w bazie Polska Bibliografia Lekarska GBL

Zapytanie: KRYCZKA
Liczba odnalezionych rekordów: 5



Przejście do opcji zmiany formatu | Wyświetlenie wyników w wersji do druku

1/5

Tytuł oryginału: A multi-center open study to determine the effect of lamivudine on HBV DNA clearance and to assess the safety of the regimen in patietns with chronic hepatitis B infection.
Autorzy: Mazur Włodzimierz, Król Franciszek, Cianciara Janusz, Nazzal Khalil, Gładysz Andrzej, Juszczyk Jacek, Bolewska Beata, Adamek Jacek, Czajka Barbara, Świętek Katarzyna, Kryczka Wiesław, Gonciarz Zbigniew
Źródło: Med. Sci. Monitor 2002: 8 (4) s.CR257-CR262, il., tab., bibliogr. 19 poz.
Sygnatura GBL: 313,278

Hasła klasyfikacyjne GBL:
  • genetyka
  • mikrobiologia
  • farmacja
  • gastroenterologia

    Typ dokumentu:
  • praca kliniczna
  • tytuł obcojęzyczny

    Wskaźnik treści:
  • ludzie
  • dorośli 19-44 r.ż.
  • dorośli 45-64 r.ż.
  • dorośli = 65 r.ż.
  • płeć męska
  • płeć żeńska

    Streszczenie angielskie: Background: Patietns with on-going HBV viral replication often present with clinical features of active chronic hepatitis. Until the recent introduction of nucleoside analogues, interferon-alpha was the only approved drug for these patietns. One of the former drugs, lamivudine, has been shown in clinical trials in the US and Asia to effectively inhibit the viral polymerase of HBV. Our study was undertaken to assess the efficacy and safety of lamivudine therapy in Polish patietns with chronic hepatitis B. Material/Methods: Forty-five patients with chronic hepatitis B (HBeAg positive, anti-e negative, HBV-DNA positive by hybridization assay) were enrolled in the study. The patietns received 100 mg of lamivudine orally, once daily for 12 months. They returned for routine clinical and laboratory control every two weeks during the first months of treatment, and later at 3-month intervals whle receiving lamivudine. Results: At the end of treatment, serum HBeAg was not detected in 21 patients (48.8 p.c.), and anti-HBe appeared in the serum of 19 patients. 37.2 p.c. of the patietns in the study group showed sustained suppression of serum HBV DNA at the end of treatment. Lamivudine therapy was well tolerated, with the rate of occurrence of adverse events similar to that observed in other clincial studies. Conclusions: 12-month lamivudine therapy in this Polish population of patients with chronic hepatitis B induced a high rate of HBeAg seroconversion, accompaneid by reduction of HBV-DNA and the normalization of alanine aminotransferase activities.


    2/5

    Tytuł oryginału: 5' - Esters of 2'-deoxyadenosine and 2-chloro-2'-deoxyadenosine with cell differentiation-provoking agents.
    Autorzy: Grieb Paweł, Kryczka Tomasz, Wójtowicz Radosław, Kawiak Jerzy, Kazimierczuk Zygmunt
    Źródło: Acta Bioch. Pol. 2002: 49 (1) s.129-137, il., bibliogr. 20 poz. - 8 Międzynarodowe Sympozjum pt. Aspekty molekularne chemioterapii Gdańsk 09. 2001
    Sygnatura GBL: 303,116

    Typ dokumentu:
  • praca związana ze zjazdem
  • praca doświadczalna
  • tytuł obcojęzyczny

    Streszczenie angielskie: Phenylacetic and retinoic acids are carboxyacidic cell differentiating agents displaying anticancer activities. We report on a new class of compounds including the 5'-esters of 2'-deoxyadenosine (dA) or 2-chloro-2'-deoxyadenosine (cladribine, 2CdA) and the aforementioned acids. The rationale behind the synthesis of these esters was that if they are hydrolyzed inside the lymphoid cells, either dA will be removed from the intracellular environment by deamination, or 2CdA will be phosphorylated and accumulated. In either case targetted delivery of the differentiating agent to the lymphoid cells may be envisaged. The said compounds were synthesized by the Mitsunobu procedure employing triphenylphosphine and azadircarboxylic acid esters, and their stability was tested against various esterases. Esters of dA and 2CdA with phenylacetic acids were found to be resistant to enzymatic hydrolysis, whereas those with retinoic acids were efficiently hydrolyzed by commercially available hepatic esterase as well as by esterases present in the blood plasma and in diluted human lymphocyte lysate. Susceptibility to enzymatic hydrolysis was found to be a prerequisite of cytotoxic and/or differentiating activity of these esters in leukemic cell lines.


    3/5

    Tytuł oryginału: In vitro releas of cytotoxic nucleoside analogs from lactide-caprolactone and lactide-glycolide copolymers.
    Autorzy: Kryczka Tomasz, Bero Maciej, Kasperczyk Janusz, Dobrzyński Piotr, Marciniec Barbara, Popielarz-Brzezińska Maria, Grieb Paweł
    Źródło: Acta Bioch. Pol. 2002: 49 (1) s.205-210, il., tab., bibliogr. 19 poz. - 8 Międzynarodowe Sympozjum pt. Aspekty molekularne chemioterapii Gdańsk 09. 2001
    Sygnatura GBL: 303,116

    Hasła klasyfikacyjne GBL:
  • farmacja
  • neurologia
  • onkologia

    Typ dokumentu:
  • praca związana ze zjazdem
  • praca doświadczalna
  • tytuł obcojęzyczny

    Wskaźnik treści:
  • in vitro

    Streszczenie angielskie: The aims of our study were to assess the release of cytotoxic nucleoside analgs 5-fluorouracil and 2-chloro-2'-deoxyadenosine from different lactide-glycolide or lactide-caprolactone biodegradable copolymers and the effects of sterilization on this release. The polymers were strilized either with ethylene oxide at 37řC, or with gamma radiation (15 kGy, 20 kGy, or 25 kBy). The kinetics of nucleoside release form the copolymers were measured over 50 days. Four copolymers exhibited realtively constant release of nucleosides in micromolar concentrations during the entire oberslightly influence nucleosides in micromolar concentrations during the entire observation period. Sterilization with either ethylene oxide or gamma radiation only slightly influence nucleoside release. Further development of these copolymers as an intracerebral nucleoside delivery system for local treatment of brain tumors is indicated.


    4/5

    Tytuł oryginału: HLA DRB1 alleles in HCV RNA positive patients with and without anti-HCV antibodies: relationship with the outcome of infections.
    Autorzy: Brojer Ewa, Kryczka Wiesław, Kalińska Aleksandra, Medyńska Joanna, Żupańska Barbara
    Źródło: Centr. Eur. J. Immunol. 2002: 27 (2) s.53-57, tab., bibliogr. 26 poz.
    Sygnatura GBL: 313,243

    Hasła klasyfikacyjne GBL:
  • genetyka
  • immunologia
  • choroby zakaźne

    Typ dokumentu:
  • praca kliniczna
  • tytuł obcojęzyczny

    Wskaźnik treści:
  • ludzie
  • dorośli 19-44 r.ż.
  • dorośli 45-64 r.ż.
  • dorośli = 65 r.ż.
  • płeć męska
  • płeć żeńska

    Streszczenie angielskie: In some individuals infected with HCV, the anti-HCV is not detectable and HCV RNA is the only marker of the infection. Since the formation of certain antibodies is MHC restricted, we evaluated whether there are differences in the HLA DRB1 allele frequency between anti-HCV negative and positive hepatitis patients, and whether the DRB1 frequency difers between patients with self-limited and chronic infection. Material: 167 HCVRNA positive (37 anti-HCV negative to end of follow-up) patients, including 42 with acute hepatitis and 125 chronic hepatitis patients; control group of 286 healthy individuals. After the follow-up for at leats 30 months the patients were divided into 2 groups: those with self-limited and those with chronic hepatitis. Other reasons of hepatitis and obvious immune defects were excluded. Methods: HCV RNA by RT PCR, antiHCV by the third generation EIA; DRB1 by INNOLiPA DRB1. Results: We found no difference in the frequency of DRB1 alleles between the healthy individuals and HCV infected patients nor between the anti-HCV negative and positive patients. However, the frequency of DRB1*15 and DRB1*11 observed in the patients with self-limited infection was significantly higher than that in the patients with chronic infection. This difference was independent of anti-HCV delectability.


    5/5

    Tytuł oryginału: Ostre zapalenie wątroby typu C.
    Tytuł angielski: Acute hepatitis C.
    Autorzy: Kryczka Wiesław
    Źródło: Prz. Epidemiol. 2002: 56 supl. 5: VII Warsztaty Hepatologiczne s.54-61, tab., bibliogr. 29 poz. - 7 Warsztaty Hepatologiczne Ustroń Śląski 15-17.05. 2002
    Sygnatura GBL: 301,250

    Hasła klasyfikacyjne GBL:
  • choroby zakaźne
  • gastroenterologia

    Typ dokumentu:
  • praca kliniczna
  • praca związana ze zjazdem

    Wskaźnik treści:
  • ludzie
  • dzieci 13-18 r.ż.
  • dorośli 19-44 r.ż.
  • dorośli 45-64 r.ż.
  • dorośli = 65 r.ż.
  • płeć męska
  • płeć żeńska

    Streszczenie angielskie: Objective: The aim of the study was both to evaluate the natural outcome of acute hepatitis C (AHC), in this factors influencing chronicity of HCV, and to assess results of antivital therapy in acute phase of disease. Patients and methods: Seventy-seven pts with diagnosis of AHC (all HCVRNA - positive, in this 44 anti-HCV-positive at entry) were seen. Sixty-four of them (F/M: 33/31; mean age: 45,4y +/-16,0) were non-treated (NT pts) with IFN during 6-months follow-up and thirteen patients (F/M: 5/8; mean age: 36,6ys +/-11,9) were treated (T pts) within INF. Antiviral therapy was started within 2 to 18 (median 10) weeeks after the onset of AHC including seven pts with IFN alpha-2b at 5MU thrice weekly (TIW) and one pt with IFN-alpha-2a at 6MU TIW for 24 weeks, three pts with combined (Rebetron) therapy according to HCV genotype (1F/3a for 24 weeks and 2M/1b for 48 weeks) and two pts with PEG-Intron for one month followed by Intron at 3MU TIW for 20 weeks. Results: 64,1 p.c. of NT pts developed chronic hepatitis. In multivariate logistic regression analysis age 40y, nonicteric course and medical procedures as route of infection were independently and significantly associated with chronicity. Ten of the thirteen (77 p.c.) treated pts presented sustained response (SR) at the end of follow-up. Only one seronegative pt no responded to the therapy. The others 12 pts (all seropositive) presented rapid normalisation of ALT levels. However, 3 of them developed breakthrough between 12 and 20 wee of therapy and ribavirin was added with...

    stosując format: